Loss of CDX2 expression is associated with poor prognosis in colorectal cancer patients

Table 1 Expression of CK7, CK20 and CDX2 in colorectal cancers according to CpG island methylator phenotype and microsatellite instability status

	CIMP			MSI
	CIMP-0, low	CIMP-high	P value1	MSS, MSI-low	MSI-high	P value1
CK7	5.7 ± 20.5	18.7 ± 37.5	0.004	6.0 ± 21.2	12.6 ± 30.7	0.082
CK20	83.5 ± 26.4	69.2 ± 37.3	0.022	84.8 ± 25.0	58.9 ± 39.1	< 0.001
CDX2 (CDX2-88)	87.7 ± 20.1	48.3 ± 42.4	< 0.001	86.8 ± 21.8	67.3 ± 38.3	< 0.001
CDX2 (EPR2764Y)	95.6 ± 19.1	56.7 ± 47.8	< 0.001	93.8 ± 22.8	85.5 ± 33.8	0.036

¹Wilcoxon’s rank-sum test. CIMP: CpG island methylator phenotype; MSI: Microsatellite instability; MSS: Microsatellite stable; CK: Cytokeratin.